Free Trial

Pediatrix Medical Group (MD) Financials

Pediatrix Medical Group logo
$13.84 +0.28 (+2.06%)
Closing price 05/27/2025 03:59 PM Eastern
Extended Trading
$13.85 +0.01 (+0.07%)
As of 05/27/2025 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Pediatrix Medical Group

Annual Income Statements for Pediatrix Medical Group

This table shows Pediatrix Medical Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Income / (Loss) Attributable to Common Shareholders
-99 -60 66 131 -796 -1,498 269 320 325 336 317
Consolidated Net Income / (Loss)
-99 -60 66 131 -796 -1,498 269 320 325 336 317
Net Income / (Loss) Continuing Operations
-99 -60 63 108 -9.58 42 122 305 325 336 317
Total Pre-Tax Income
-101 -48 81 135 7.15 59 166 386 514 540 509
Total Operating Income
-69 7.32 173 203 98 172 248 455 572 558 513
Total Gross Profit
2,013 1,995 1,972 1,911 1,734 1,780 1,723 3,253 3,183 2,780 2,439
Total Revenue
2,013 1,995 1,972 1,911 1,734 1,780 1,723 3,253 3,183 2,780 2,439
Operating Revenue
2,013 1,995 1,972 1,911 1,734 1,780 1,723 3,253 3,183 2,780 2,439
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
2,082 1,987 1,799 1,723 1,636 1,608 1,475 2,798 2,611 2,222 1,926
Selling, General & Admin Expense
1,679 1,676 1,615 1,561 1,443 1,425 1,358 2,613 2,404 2,059 1,791
Depreciation Expense
32 36 36 32 28 26 24 79 89 64 46
Other Operating Expenses / (Income)
127 125 122 100 91 96 92 106 118 98 89
Impairment Charge
178 148 0.00 0.00 - - - 0.00 - - -
Restructuring Charge
64 2.22 27 22 74 61 0.00 0.00 - - -
Total Other Income / (Expense), net
-33 -56 -91 -68 -91 -113 -82 -69 -58 -18 -4.38
Interest Expense
41 42 97 83 110 119 93 75 63 23 8.89
Interest & Investment Income
8.12 6.40 5.39 16 19 5.96 11 5.34 5.20 4.97 4.51
Other Income / (Expense), net
0.00 -20 0.00 0.00 - 0.00 - - - - -
Income Tax Expense
-2.27 12 19 27 17 17 45 80 189 204 191
Net Income / (Loss) Discontinued Operations
0.00 0.00 3.77 23 -787 -1,540 147 15 - - -
Net Income / (Loss) Attributable to Noncontrolling Interest
0.00 0.00 -0.00 -0.03 0.00 0.00 - - -0.32 -0.63 -0.08
Basic Earnings per Share
($1.19) ($0.73) $0.79 $1.54 ($9.55) ($17.94) $2.95 $3.47 $3.52 $3.61 $3.22
Weighted Average Basic Shares Outstanding
83.33M 82.20M 83.47M 84.83M 83.40M 83.50M 91.10M 92.43M 92.42M 93.08M 98.59M
Diluted Earnings per Share
($1.19) ($0.73) $0.79 $1.53 ($9.55) ($17.83) $2.93 $3.45 $3.49 $3.58 $3.18
Weighted Average Diluted Shares Outstanding
83.33M 82.20M 84.12M 85.83M 83.40M 84.01M 91.61M 92.96M 93.11M 93.96M 99.89M
Weighted Average Basic & Diluted Shares Outstanding
85.83M 84.12M 83.03M 86.47M 85.63M 84.28M 91.10M 92.30M 93.79M 93.20M 98.50M

Quarterly Income Statements for Pediatrix Medical Group

This table shows Pediatrix Medical Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
22 28 21 -153 4.10 -125 21 28 15 30 31
Consolidated Net Income / (Loss)
21 30 19 -153 4.04 -124 21 28 14 30 31
Net Income / (Loss) Continuing Operations
21 30 19 -153 4.04 -124 21 28 14 24 29
Total Pre-Tax Income
28 33 25 -168 7.82 -139 31 39 21 28 39
Total Operating Income
32 39 34 -158 16 -111 40 48 30 36 47
Total Gross Profit
458 502 511 504 495 496 507 501 491 514 490
Total Revenue
458 502 511 504 495 496 507 501 491 514 490
Operating Revenue
458 502 511 504 495 496 507 501 491 514 490
Total Cost of Revenue
0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses
426 463 477 662 479 608 466 452 461 478 443
Selling, General & Admin Expense
396 413 423 414 429 417 426 412 421 418 401
Depreciation Expense
5.33 6.87 6.25 8.79 10 9.06 9.21 8.95 8.95 9.14 8.96
Other Operating Expenses / (Income)
19 24 30 43 31 32 31 31 31 31 32
Restructuring Charge
6.61 24 19 14 8.48 2.22 0.00 0.00 0.00 20 0.98
Total Other Income / (Expense), net
-4.01 -5.96 -8.59 -10 -8.07 -27 -9.44 -9.55 -9.33 -8.21 -8.53
Interest Expense
9.15 9.71 10 10 11 10 10 11 10 9.95 9.52
Interest & Investment Income
5.14 3.75 1.53 0.30 2.53 2.72 0.93 1.68 1.06 1.74 0.99
Income Tax Expense
7.35 2.85 5.79 -15 3.79 -15 9.44 11 6.51 3.82 10
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)
-0.78 - -1.75 -0.20 -0.06 - - 0.39 -0.60 - -
Basic Earnings per Share
$0.25 $0.37 $0.23 ($1.84) $0.05 ($1.50) $0.26 $0.34 $0.17 $0.35 $0.37
Weighted Average Basic Shares Outstanding
84.44M 83.33M 83.89M 83.33M 82.86M 82.20M 82.54M 82.40M 81.89M 83.47M 82.13M
Diluted Earnings per Share
$0.24 $0.37 $0.23 ($1.84) $0.05 ($1.50) $0.26 $0.34 $0.17 $0.35 $0.37
Weighted Average Diluted Shares Outstanding
85.43M 83.33M 84.52M 83.33M 83.28M 82.20M 82.95M 82.66M 82.32M 84.12M 82.78M
Weighted Average Basic & Diluted Shares Outstanding
85.91M 85.83M 85.88M 85.87M 84.15M 84.12M 84.02M 83.94M 83.76M 83.03M 83.07M

Annual Cash Flow Statements for Pediatrix Medical Group

This table details how cash moves in and out of Pediatrix Medical Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Change in Cash & Equivalents
157 63 -378 -736 1,016 161 0.33 25 4.13 3.64 17
Net Cash From Operating Activities
207 137 167 77 205 358 314 511 444 369 423
Net Cash From Continuing Operating Activities
217 146 182 114 154 74 59 483 444 369 423
Net Income / (Loss) Continuing Operations
-99 -60 63 108 -9.58 42 122 305 325 336 317
Consolidated Net Income / (Loss)
-99 -60 66 131 -796 -1,498 269 320 325 336 317
Net Income / (Loss) Discontinued Operations
0.00 0.00 3.77 23 -787 -1,540 147 15 - - -
Depreciation Expense
32 36 36 32 28 26 24 79 89 64 46
Amortization Expense
0.95 1.24 1.77 4.34 7.16 5.67 4.57 5.51 4.82 1.54 1.23
Non-Cash Adjustments To Reconcile Net Income
197 177 73 38 39 40 34 51 31 31 26
Changes in Operating Assets and Liabilities, net
86 -8.39 9.06 -55 89 -40 -125 42 -5.66 -64 32
Net Cash From Discontinued Operating Activities
-11 -8.76 -15 -37 51 284 255 28 - - -
Net Cash From Investing Activities
-35 -48 -57 -53 816 102 -143 -577 -821 -848 -504
Net Cash From Continuing Investing Activities
-35 -48 -57 -55 -58 -50 -85 -553 -821 -848 -504
Purchase of Property, Plant & Equipment
-22 -33 -30 -32 -29 -19 -17 -26 -39 -27 -18
Acquisitions
-8.17 -6.67 -28 -30 -2.23 47 -65 -531 -762 -819 -479
Purchase of Investments
-65 -32 -17 -35 -62 -35 -16 -28 -61 -34 -27
Sale of Property, Plant & Equipment
6.84 0.81 1.38 25 1.08 0.00 - - - - -
Sale and/or Maturity of Investments
52 23 17 16 33 51 14 25 41 32 21
Net Cash From Financing Activities
-14 -26 -488 -760 -4.16 -393 -171 90 382 483 98
Net Cash From Continuing Financing Activities
0.00 0.00 0.00 -760 -2.91 -384 -169 90 382 483 98
Repayment of Debt
-248 -495 -1,882 -759 -528 -1,996 -2,102 -2,704 -1,512 -2,172 -1,218
Repurchase of Common Equity
-1.70 -0.92 -89 -4.72 -8.49 -145 -302 -70 -62 -235 -488
Issuance of Debt
236 470 1,480 0.00 528 1,747 2,224 2,846 1,940 2,872 1,755
Issuance of Common Equity
3.64 4.91 5.40 6.85 7.25 11 16 24 22 20 44
Other Financing Activities, net
-4.06 -4.44 -2.92 -3.00 -1.16 -1.39 -5.26 -5.45 -6.50 -1.27 5.72
Net Cash From Discontinued Financing Activities
0.00 0.00 0.00 0.00 -1.25 -8.96 -1.36 -0.61 - - -
Cash Interest Paid
40 42 116 87 110 95 83 74 60 20 7.32
Cash Income Taxes Paid
4.67 31 27 55 -28 86 185 75 176 181 162

Quarterly Cash Flow Statements for Pediatrix Medical Group

This table details how cash moves in and out of Pediatrix Medical Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-131 126 84 11 -65 52 15 -0.28 -3.70 1.16 -5.42
Net Cash From Operating Activities
-117 133 92 107 -125 69 80 89 -101 99 83
Net Cash From Continuing Operating Activities
-116 135 96 109 -123 73 81 93 -101 102 88
Net Income / (Loss) Continuing Operations
21 30 19 -153 4.04 -124 21 28 14 24 29
Consolidated Net Income / (Loss)
21 30 19 -153 4.04 -124 21 28 14 30 31
Depreciation Expense
5.33 6.87 6.25 8.79 10 9.06 9.21 8.95 8.95 9.14 8.96
Amortization Expense
0.23 0.25 0.26 0.24 0.20 0.22 0.28 0.34 0.39 0.42 0.49
Non-Cash Adjustments To Reconcile Net Income
2.88 -3.06 3.84 194 1.80 170 2.46 2.62 2.62 5.76 3.32
Changes in Operating Assets and Liabilities, net
-145 100 66 59 -139 18 48 52 -127 63 47
Net Cash From Discontinued Operating Activities
-1.35 -1.80 -3.89 -2.39 -2.60 -3.75 -1.18 -3.55 -0.27 -3.61 -5.02
Net Cash From Investing Activities
-7.46 -1.94 -4.34 -13 -16 -12 -14 -10 -11 -11 -6.09
Net Cash From Continuing Investing Activities
-7.46 -1.94 -4.34 -29 0.00 -12 -14 -22 0.00 -57 -
Purchase of Property, Plant & Equipment
-3.32 -3.44 -6.29 -6.96 -5.33 -9.04 -9.15 -8.13 -7.00 -9.06 -6.95
Acquisitions
0.00 - - - -8.17 -5.00 - - -1.67 - -
Purchase of Investments
-7.76 -10 -14 -23 -17 -5.42 -8.72 -8.21 -9.55 -2.41 -1.96
Sale and/or Maturity of Investments
7.30 7.17 14 17 14 6.35 3.75 5.95 6.87 1.00 1.85
Other Investing Activities, net
-3.69 - - - - - - - - - -
Net Cash From Financing Activities
-6.04 -4.96 -3.07 -83 76 -4.75 -51 -79 109 -86 -83
Net Cash From Continuing Financing Activities
-6.04 9.52 -3.07 -83 76 21 -51 -79 109 401 -83
Repayment of Debt
-4.79 -12 6.22 -148 -94 -3.45 -100 -285 -107 -241 -261
Repurchase of Common Equity
-1.57 -0.64 -0.16 -0.01 -0.89 - -0.13 -0.01 -0.78 -1.47 -21
Issuance of Debt
0.00 - - 65 171 - 49 205 216 156 200
Issuance of Common Equity
0.66 0.73 0.90 1.15 0.86 1.04 1.19 1.59 1.10 1.18 1.38
Other Financing Activities, net
-0.34 7.37 -10 -0.70 -0.69 -2.33 -0.70 -0.70 -0.70 -0.74 -0.91

Annual Balance Sheets for Pediatrix Medical Group

This table presents Pediatrix Medical Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Total Assets
2,153 2,220 2,348 2,723 3,348 4,146 5,937 5,867 5,339 4,547 3,608
Total Current Assets
640 483 428 841 1,549 732 660 627 587 528 467
Cash & Equivalents
230 73 9.82 387 1,124 108 25 60 56 52 48
Short-Term Investments
119 104 93 100 105 75 22 10 11 8.85 6.04
Accounts Receivable
260 272 297 302 242 434 507 504 495 445 352
Prepaid Expenses
13 14 15 19 17 17 17 16 11 9.64 7.04
Current Deferred & Refundable Income Taxes
13 7.57 0.00 14 0.00 - - - - - 46
Other Current Assets
5.09 12 13 19 62 12 17 37 14 13 7.90
Plant, Property, & Equipment, net
39 76 73 70 76 73 90 124 103 84 66
Total Noncurrent Assets
1,474 1,661 1,847 1,812 1,722 3,342 5,187 5,117 4,649 3,936 3,075
Goodwill
1,243 1,384 1,532 1,505 1,478 1,480 4,061 4,284 3,845 3,366 2,776
Intangible Assets
12 21 18 22 27 29 313 640 669 424 198
Noncurrent Deferred & Refundable Income Taxes
104 103 106 88 54 87 22 - - - -
Other Noncurrent Operating Assets
116 152 190 196 163 105 81 112 57 82 37
Total Liabilities & Shareholders' Equity
2,153 2,220 2,348 2,723 3,348 4,146 5,937 5,867 5,339 4,547 3,608
Total Liabilities
1,388 1,371 1,456 1,826 2,600 2,647 2,850 2,801 2,579 2,109 1,343
Total Current Liabilities
434 389 427 427 444 542 503 531 449 429 416
Short-Term Debt
21 15 15 2.49 - - 0.25 1.40 22 12 10
Accounts Payable
399 351 374 394 423 411 449 438 408 396 381
Current Deferred & Payable Income Tax Liabilities
2.17 2.16 16 11 0.00 6.04 31 92 19 21 25
Other Current Liabilities
13 21 22 20 21 18 0.00 - - - -
Total Noncurrent Liabilities
954 982 1,029 1,398 2,156 2,105 2,347 2,269 2,130 1,681 926
Long-Term Debt
597 618 636 0.00 1,743 1,730 1,974 1,851 1,684 1,263 558
Noncurrent Deferred & Payable Income Tax Liabilities
34 34 34 41 62 56 96 148 228 189 160
Other Noncurrent Operating Liabilities
322 329 359 1,357 352 272 241 270 218 229 208
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
765 849 892 897 748 1,499 3,088 3,066 2,761 2,438 2,266
Total Preferred & Common Equity
765 849 892 896 747 1,499 3,088 3,066 2,761 2,438 2,265
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
765 849 892 896 747 1,499 3,088 3,066 2,761 2,438 2,265
Common Stock
1,015 1,001 984 1,051 1,030 989 994 1,018 975 927 888
Retained Earnings
-249 -149 -89 -155 -286 510 2,094 2,048 1,786 1,510 1,377
Accumulated Other Comprehensive Income / (Loss)
-1.07 -2.21 -3.74 1.32 3.53 0.08 - - - - -

Quarterly Balance Sheets for Pediatrix Medical Group

This table presents Pediatrix Medical Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
1,993 2,077 1,995 2,168 2,326 2,306 2,320 2,332
Total Current Assets
492 528 429 427 421 398 409 424
Cash & Equivalents
99 104 19 8.00 21 5.85 6.12 8.67
Short-Term Investments
120 117 114 107 104 98 97 91
Accounts Receivable
243 287 274 284 277 271 279 294
Prepaid Expenses
12 10 12 13 11 12 15 9.66
Current Deferred & Refundable Income Taxes
10 1.20 0.00 5.19 - - - 9.73
Other Current Assets
7.61 9.48 9.94 9.58 7.87 10 12 9.90
Plant, Property, & Equipment, net
38 42 48 74 75 73 73 72
Total Noncurrent Assets
1,464 1,507 1,518 1,667 1,831 1,834 1,839 1,837
Noncurrent Note & Lease Receivables
40 - - 70 - - 67 -
Goodwill
1,243 1,239 1,239 1,393 1,532 1,532 1,532 1,532
Intangible Assets
10 13 10 19 15 17 17 20
Noncurrent Deferred & Refundable Income Taxes
99 119 124 102 103 102 103 98
Other Noncurrent Operating Assets
71 135 145 83 180 184 119 187
Total Liabilities & Shareholders' Equity
1,993 2,077 1,995 2,168 2,326 2,306 2,320 2,332
Total Liabilities
1,204 1,344 1,289 1,312 1,358 1,363 1,410 1,473
Total Current Liabilities
271 373 310 247 350 320 284 352
Short-Term Debt
22 19 18 16 15 15 15 15
Accounts Payable
234 333 267 207 303 278 227 306
Current Deferred & Payable Income Tax Liabilities
2.58 3.32 6.33 2.80 11 6.15 22 7.66
Other Current Liabilities
12 17 19 21 22 22 21 23
Total Noncurrent Liabilities
933 971 979 1,065 1,008 1,043 1,126 1,122
Long-Term Debt
590 0.00 0.00 80 622 666 114 731
Noncurrent Deferred & Payable Income Tax Liabilities
34 36 31 34 41 38 33 40
Other Noncurrent Operating Liabilities
308 936 948 951 345 339 979 351
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
789 732 706 856 968 942 910 859
Total Preferred & Common Equity
789 732 706 856 968 942 910 859
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
789 732 706 856 968 942 910 859
Common Stock
1,017 1,012 1,007 1,004 997 992 988 981
Retained Earnings
-228 -279 -298 -145 -25 -47 -75 -119
Accumulated Other Comprehensive Income / (Loss)
-0.29 -0.21 -1.95 -2.15 -3.52 -3.52 -3.13 -4.10

Annual Metrics And Ratios for Pediatrix Medical Group

This table displays calculated financial ratios and metrics derived from Pediatrix Medical Group's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.92% 1.15% 3.18% 10.22% -2.57% 3.29% -47.04% 2.21% 14.50% 13.99% 13.23%
EBITDA Growth
-243.68% -88.23% -12.24% 79.01% -34.24% -26.67% -48.58% -19.00% 6.76% 11.32% 13.84%
EBIT Growth
-441.94% -107.34% -14.90% 106.78% -42.87% -30.85% -45.40% -20.43% 2.48% 8.75% 13.46%
NOPAT Growth
-1,038.57% -96.14% -18.06% 223.21% -206.65% -32.09% -49.59% -0.25% 4.09% 8.45% 13.11%
Net Income Growth
-64.00% -191.07% -49.34% 116.44% 46.82% -657.54% -16.15% -1.30% -3.31% 5.83% 13.08%
EPS Growth
-63.01% -192.41% -48.37% 116.02% 46.44% -708.53% -15.07% -1.15% -2.51% 12.58% 14.39%
Operating Cash Flow Growth
50.43% -17.74% 117.55% -62.50% -42.80% 14.03% -38.65% 15.23% 20.36% -12.76% 4.25%
Free Cash Flow Firm Growth
58.53% 115.68% -188.48% 1,178.17% -97.31% 348.77% 851.15% 76.42% 29.51% -333.50% -208.28%
Invested Capital Growth
-20.74% -9.39% 249.41% -67.34% -14.31% -65.71% -9.95% 10.36% 20.39% 32.12% 19.39%
Revenue Q/Q Growth
0.30% -0.86% 0.78% 4.48% 41.00% 73.79% -47.34% -3.70% 2.88% 3.39% 3.53%
EBITDA Q/Q Growth
80.70% -87.15% -12.89% 16.32% 58.31% 114.35% -44.13% -10.67% -0.10% 2.58% 4.05%
EBIT Q/Q Growth
68.69% -108.19% -15.62% 21.35% 91.77% 58.25% -41.80% -8.50% -1.41% 1.80% 3.46%
NOPAT Q/Q Growth
68.69% -95.54% -11.90% 23.58% -467.16% 62.32% -52.48% 18.80% -2.64% 2.09% 3.35%
Net Income Q/Q Growth
60.97% -164.58% -21.21% 584.42% -10.19% -3.52% -22.03% 22.12% -4.23% 1.25% 3.02%
EPS Q/Q Growth
25.63% -165.18% -20.20% 800.00% -12.22% -2.59% -21.02% 22.34% -4.90% 0.28% 2.25%
Operating Cash Flow Q/Q Growth
44.65% -17.65% 48.40% 271.88% -41.83% -4.30% -12.36% 14.48% 6.43% -16.84% 10.33%
Free Cash Flow Firm Q/Q Growth
-72.02% 0.48% 7.21% 244.09% -97.74% 52.66% 489.25% -660.18% 1.18% 8.64% -77.61%
Invested Capital Q/Q Growth
94.63% -11.84% -4.30% 5.86% 384.20% -51.24% -11.88% 3.62% 0.16% 0.59% 2.40%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
-1.77% 1.24% 10.65% 12.53% 7.71% 11.43% 16.09% 16.58% 20.92% 22.43% 22.97%
Operating Margin
-3.41% 0.37% 8.76% 10.62% 5.66% 9.65% 14.42% 13.98% 17.96% 20.07% 21.03%
EBIT Margin
-3.41% -0.64% 8.76% 10.62% 5.66% 9.65% 14.42% 13.98% 17.96% 20.07% 21.03%
Profit (Net Income) Margin
-4.92% -3.03% 3.36% 6.85% -45.93% -84.15% 15.59% 9.85% 10.20% 12.08% 13.01%
Tax Burden Percent
97.76% 124.92% 81.52% 96.83% -11,142.81% -2,547.81% 161.62% 83.07% 63.18% 62.20% 62.37%
Interest Burden Percent
147.48% 381.41% 47.12% 66.64% 7.28% 34.23% 66.91% 84.78% 89.87% 96.75% 99.15%
Effective Tax Rate
0.00% 0.00% 23.11% 20.14% 234.02% 28.20% 26.89% 20.80% 36.82% 37.80% 37.63%
Return on Invested Capital (ROIC)
-4.11% 0.37% 14.34% 19.36% -9.62% 4.28% 4.01% 7.93% 9.13% 11.01% 12.82%
ROIC Less NNEP Spread (ROIC-NNEP)
-18.18% -12.68% -194.61% -193.26% -282.64% -270.72% 10.00% 5.48% 6.43% 9.60% 11.39%
Return on Net Nonoperating Assets (RNNOA)
-8.16% -7.31% -6.92% -3.44% -61.28% -69.58% 4.72% 3.07% 3.36% 3.27% 0.95%
Return on Equity (ROE)
-12.28% -6.94% 7.42% 15.93% -70.90% -65.30% 8.73% 11.00% 12.49% 14.27% 13.77%
Cash Return on Invested Capital (CROIC)
19.02% 10.23% -96.66% 120.88% 5.79% 102.14% 14.48% -1.92% -9.37% -16.67% -4.86%
Operating Return on Assets (OROA)
-3.14% -0.56% 6.81% 6.69% 2.62% 3.41% 4.21% 8.12% 11.56% 13.68% 15.51%
Return on Assets (ROA)
-4.53% -2.65% 2.62% 4.31% -21.26% -29.71% 4.55% 5.72% 6.57% 8.23% 9.59%
Return on Common Equity (ROCE)
-12.28% -6.94% 7.42% 15.92% -70.90% -65.30% 8.73% 11.00% 12.49% 14.27% 13.76%
Return on Equity Simple (ROE_SIMPLE)
-12.95% -7.11% 7.44% 14.61% -106.56% -99.91% 8.70% 10.45% 11.76% 13.77% 14.01%
Net Operating Profit after Tax (NOPAT)
-48 5.12 133 162 -132 123 182 360 361 347 320
NOPAT Margin
-2.39% 0.26% 6.73% 8.48% -7.59% 6.93% 10.54% 11.07% 11.35% 12.48% 13.12%
Net Nonoperating Expense Percent (NNEP)
14.07% 13.06% 208.95% 212.63% 273.02% 275.00% -5.99% 2.45% 2.70% 1.41% 1.43%
Return On Investment Capital (ROIC_SIMPLE)
-3.48% 0.35% 8.61% - - - - - - - -
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
83.42% 84.02% 81.88% 81.67% 83.21% 80.08% 78.80% 80.32% 75.52% 74.08% 73.43%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
103.41% 99.63% 91.24% 90.14% 94.34% 90.35% 85.58% 86.02% 82.04% 79.93% 78.97%
Earnings before Interest and Taxes (EBIT)
-69 -13 173 203 98 172 248 455 572 558 513
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-36 25 210 239 134 203 277 539 666 624 560
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.47 0.92 1.38 2.62 2.81 1.56 0.96 1.63 2.26 2.76 2.93
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.56 0.39 0.63 1.23 1.21 1.32 1.71 1.54 1.96 2.42 2.72
Price to Earnings (P/E)
0.00 0.00 18.61 17.96 0.00 0.00 10.98 15.62 19.21 20.04 20.92
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 5.37% 5.57% 0.00% 0.00% 9.10% 6.40% 5.21% 4.99% 4.78%
Enterprise Value to Invested Capital (EV/IC)
1.35 0.95 1.24 4.53 2.07 2.64 1.12 1.41 1.81 2.20 2.61
Enterprise Value to Revenue (EV/Rev)
0.69 0.62 0.90 0.98 1.51 2.19 2.78 2.06 2.45 2.84 2.91
Enterprise Value to EBITDA (EV/EBITDA)
0.00 50.02 8.49 7.80 19.55 19.13 17.27 12.44 11.72 12.65 12.66
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 10.32 9.21 26.64 22.65 19.28 14.74 13.65 14.14 13.82
Enterprise Value to NOPAT (EV/NOPAT)
0.00 241.38 13.43 11.53 0.00 31.55 26.37 18.62 21.60 22.74 22.16
Enterprise Value to Operating Cash Flow (EV/OCF)
6.76 9.01 10.68 24.34 12.78 10.88 15.26 13.11 17.58 21.40 16.78
Enterprise Value to Free Cash Flow (EV/FCFF)
6.28 8.82 0.00 1.85 33.04 1.32 7.30 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.81 0.75 0.73 0.00 2.33 1.15 0.64 0.60 0.62 0.52 0.25
Long-Term Debt to Equity
0.78 0.73 0.71 0.00 2.33 1.15 0.64 0.60 0.61 0.52 0.25
Financial Leverage
0.45 0.58 0.04 0.02 0.22 0.26 0.47 0.56 0.52 0.34 0.08
Leverage Ratio
2.71 2.62 2.84 3.69 3.34 2.20 1.92 1.92 1.90 1.73 1.44
Compound Leverage Factor
4.00 10.01 1.34 2.46 0.24 0.75 1.28 1.63 1.71 1.68 1.42
Debt to Total Capital
44.67% 42.72% 42.21% 0.28% 69.97% 53.58% 39.00% 37.66% 38.19% 34.34% 20.07%
Short-Term Debt to Total Capital
1.49% 1.01% 0.97% 0.28% 0.00% 0.00% 0.01% 0.03% 0.49% 0.32% 0.37%
Long-Term Debt to Total Capital
43.19% 41.72% 41.25% 0.00% 69.97% 53.58% 39.00% 37.64% 37.70% 34.01% 19.70%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.02% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.03%
Common Equity to Total Capital
55.33% 57.28% 57.79% 99.70% 30.02% 46.42% 61.00% 62.34% 61.81% 65.66% 79.90%
Debt to EBITDA
-17.38 25.61 3.10 0.01 13.03 8.51 7.12 3.44 2.56 2.04 1.02
Net Debt to EBITDA
-7.57 18.42 2.61 -2.02 3.84 7.61 6.63 3.16 2.34 1.85 0.80
Long-Term Debt to EBITDA
-16.80 25.01 3.03 0.00 13.03 8.51 7.12 3.43 2.53 2.02 1.00
Debt to NOPAT
-12.84 123.58 4.91 0.02 -13.25 14.03 10.87 5.14 4.72 3.67 1.78
Net Debt to NOPAT
-5.60 88.90 4.13 -2.99 -3.91 12.55 10.12 4.72 4.32 3.32 1.41
Long-Term Debt to NOPAT
-12.41 120.67 4.79 0.00 -13.25 14.03 10.87 5.14 4.66 3.64 1.75
Altman Z-Score
1.27 1.18 1.54 1.82 1.38 1.32 1.58 2.39 2.90 3.42 4.66
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.01% 0.03% 0.01% 0.00% 0.00% 0.00% 0.01% 0.03% 0.02%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.47 1.24 1.00 1.97 3.49 1.35 1.31 1.18 1.31 1.23 1.12
Quick Ratio
1.40 1.16 0.94 1.85 3.31 1.14 1.10 1.08 1.25 1.18 0.98
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
222 140 -895 1,012 79 2,945 656 -87 -370 -526 -121
Operating Cash Flow to CapEx
1,360.20% 422.27% 589.27% 1,106.20% 738.49% 1,856.41% 1,832.41% 1,955.56% 1,130.24% 1,361.88% 2,340.08%
Free Cash Flow to Firm to Interest Expense
5.46 3.34 -9.25 12.15 0.72 24.76 7.06 -1.17 -5.87 -22.74 -13.64
Operating Cash Flow to Interest Expense
5.07 3.26 1.73 0.92 1.85 3.01 3.38 6.86 7.03 15.95 47.54
Operating Cash Flow Less CapEx to Interest Expense
4.70 2.49 1.43 0.84 1.60 2.85 3.19 6.51 6.41 14.78 45.50
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.92 0.87 0.78 0.63 0.46 0.35 0.29 0.58 0.64 0.68 0.74
Accounts Receivable Turnover
7.56 7.01 6.59 7.03 5.13 3.78 3.41 6.51 6.77 6.98 7.65
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
35.06 26.79 27.50 26.12 23.30 21.82 16.11 28.71 34.10 37.15 38.73
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
48.26 52.07 55.39 51.92 71.17 96.49 107.05 56.05 53.89 52.32 47.71
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
48.26 52.07 55.39 51.92 71.17 96.49 107.05 56.05 53.89 52.32 47.71
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
1,034 1,305 1,440 412 1,262 1,472 4,294 4,768 4,320 3,589 2,716
Invested Capital Turnover
1.72 1.45 2.13 2.28 1.27 0.62 0.38 0.72 0.80 0.88 0.98
Increase / (Decrease) in Invested Capital
-271 -135 1,028 -850 -211 -2,821 -475 448 732 873 441
Enterprise Value (EV)
1,396 1,237 1,783 1,868 2,615 3,891 4,788 6,707 7,802 7,890 7,090
Market Capitalization
1,127 781 1,234 2,352 2,101 2,343 2,951 5,005 6,242 6,739 6,638
Book Value per Share
$8.91 $10.11 $10.73 $10.37 $8.73 $17.78 $34.53 $32.74 $29.48 $25.92 $22.55
Tangible Book Value per Share
($5.70) ($6.62) ($7.93) ($7.29) ($8.85) ($0.11) ($14.39) ($19.83) ($18.72) ($14.39) ($7.07)
Total Capital
1,383 1,482 1,543 899 2,490 3,229 5,062 4,919 4,466 3,713 2,834
Total Debt
618 633 651 2.49 1,743 1,730 1,975 1,853 1,706 1,275 569
Total Long-Term Debt
597 618 636 0.00 1,743 1,730 1,974 1,851 1,684 1,263 558
Net Debt
269 456 548 -485 514 1,548 1,837 1,702 1,560 1,151 451
Capital Expenditures (CapEx)
15 33 28 6.94 28 19 17 26 39 27 18
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-122 -68 -87 -71 -124 7.31 90 27 93 50 7.28
Debt-free Net Working Capital (DFNWC)
226 109 16 416 1,105 190 157 97 160 111 61
Net Working Capital (NWC)
205 95 1.01 413 1,105 190 157 96 138 99 51
Net Nonoperating Expense (NNE)
51 66 66 31 665 1,621 -87 40 37 11 2.73
Net Nonoperating Obligations (NNO)
269 456 548 -485 514 -27 1,206 1,702 1,560 1,151 451
Total Depreciation and Amortization (D&A)
33 37 37 36 36 32 29 84 94 66 47
Debt-free, Cash-free Net Working Capital to Revenue
-6.08% -3.43% -4.42% -3.74% -7.13% 0.41% 5.23% 0.82% 2.93% 1.82% 0.30%
Debt-free Net Working Capital to Revenue
11.23% 5.49% 0.81% 21.75% 63.73% 10.66% 9.14% 2.99% 5.03% 3.99% 2.51%
Net Working Capital to Revenue
10.21% 4.74% 0.05% 21.62% 63.73% 10.66% 9.12% 2.94% 4.34% 3.56% 2.08%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($1.19) $0.73 $0.79 $1.54 $0.00 ($17.94) $2.95 $3.47 $3.52 $3.61 $3.22
Adjusted Weighted Average Basic Shares Outstanding
83.33M 82.20M 83.47M 84.83M 0.00 83.50M 91.10M 92.43M 92.42M 93.08M 98.59M
Adjusted Diluted Earnings per Share
($1.19) $0.73 $0.79 $1.53 $0.00 ($17.94) $2.93 $3.45 $3.49 $3.58 $3.18
Adjusted Weighted Average Diluted Shares Outstanding
83.33M 82.20M 84.12M 85.83M 0.00 83.50M 91.61M 92.96M 93.11M 93.96M 99.89M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $2.95 $3.47 $3.52 $3.61 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
85.83M 84.12M 83.03M 86.47M 0.00 84.28M 87.92M 93.80M 93.79M 93.80M 96.08M
Normalized Net Operating Profit after Tax (NOPAT)
122 110 154 186 120 167 182 360 361 347 320
Normalized NOPAT Margin
6.05% 5.54% 7.80% 9.71% 6.94% 9.39% 10.54% 11.07% 11.35% 12.48% 13.12%
Pre Tax Income Margin
-5.03% -2.42% 4.13% 7.08% 0.41% 3.30% 9.65% 11.85% 16.14% 19.41% 20.85%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-1.69 -0.30 1.79 2.44 0.89 1.44 2.67 6.10 9.06 24.14 57.70
NOPAT to Interest Expense
-1.18 0.12 1.37 1.95 -1.19 1.04 1.95 4.83 5.72 15.01 35.98
EBIT Less CapEx to Interest Expense
-2.06 -1.07 1.49 2.35 0.64 1.28 2.49 5.75 8.44 22.97 55.67
NOPAT Less CapEx to Interest Expense
-1.55 -0.65 1.08 1.86 -1.44 0.87 1.77 4.48 5.10 13.84 33.95
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-1.72% -1.52% 133.44% 3.60% -1.07% -9.70% 112.48% 21.91% 19.05% 70.02% 153.98%

Quarterly Metrics And Ratios for Pediatrix Medical Group

This table displays calculated financial ratios and metrics derived from Pediatrix Medical Group's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-7.42% 1.19% 0.90% 0.74% 0.83% -3.39% 3.41% 2.99% 1.82% 3.07% -0.62%
EBITDA Growth
42.66% 145.41% -18.93% -357.33% -32.97% -324.17% -12.43% -2.41% -18.71% -40.54% -17.19%
EBIT Growth
101.99% 135.24% -16.00% -425.22% -47.10% -409.37% -15.01% -3.30% -23.18% -47.01% -19.40%
NOPAT Growth
189.15% 146.04% -6.73% -413.50% -60.22% -351.06% -20.47% -1.58% -24.73% -39.26% -18.49%
Net Income Growth
413.93% 124.52% -9.12% -641.07% -71.60% -519.05% -30.39% 4.22% 167.03% -37.57% -0.19%
EPS Growth
380.00% 124.67% -11.54% -641.18% -70.59% -528.57% -29.73% 6.25% 168.00% -36.36% 2.78%
Operating Cash Flow Growth
6.20% 92.07% 14.89% 20.10% -24.09% -29.83% -4.07% 8.07% -3.52% 123.09% 36.38%
Free Cash Flow Firm Growth
-400.98% 436.26% 1,753.56% 1,216.49% 659.68% 105.73% 104.87% 105.45% 102.78% -210.66% -36.71%
Invested Capital Growth
41.27% -20.74% -64.10% -61.10% -10.55% -9.39% -1.64% -1.74% 0.70% 249.41% 286.52%
Revenue Q/Q Growth
-8.76% -1.72% 1.36% 1.86% -0.27% -2.01% 1.21% 1.95% -4.44% 4.88% 0.80%
EBITDA Q/Q Growth
-18.86% 15.05% 127.13% -663.23% 125.83% -305.37% -13.88% 46.71% -13.61% -19.78% -4.02%
EBIT Q/Q Growth
-18.30% 16.15% 121.45% -1,092.47% 114.25% -376.84% -16.96% 61.44% -16.64% -23.95% -5.52%
NOPAT Q/Q Growth
-34.05% 37.89% 123.60% -1,447.10% 110.50% -379.32% -20.66% 70.92% -33.72% -11.51% -1.82%
Net Income Q/Q Growth
-31.97% 56.78% 112.70% -3,892.44% 103.25% -681.02% -24.37% 99.08% -52.10% -3.48% 13.24%
EPS Q/Q Growth
-35.14% 60.87% 112.50% -3,780.00% 225.00% -676.92% -23.53% 100.00% -51.43% -5.41% 15.63%
Operating Cash Flow Q/Q Growth
-188.31% 44.83% -14.13% 185.41% -280.83% -13.37% -10.24% 188.24% -202.26% 18.43% 1.12%
Free Cash Flow Firm Q/Q Growth
-204.99% -68.55% 19.17% 664.94% -84.17% 8.69% -15.36% 341.41% 101.41% 7.73% 5.26%
Invested Capital Q/Q Growth
14.36% 94.63% -10.10% -29.40% 21.99% -11.84% -2.59% 62.34% -35.00% -4.30% -2.69%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
8.22% 9.24% 7.89% -29.49% 5.33% -20.59% 9.82% 11.54% 8.02% 8.87% 11.60%
Operating Margin
7.00% 7.82% 6.62% -31.28% 3.21% -22.46% 7.95% 9.69% 6.12% 7.01% 9.67%
EBIT Margin
7.00% 7.82% 6.62% -31.28% 3.21% -22.46% 7.95% 9.69% 6.12% 7.01% 9.67%
Profit (Net Income) Margin
4.52% 6.07% 3.80% -30.34% 0.82% -25.04% 4.22% 5.65% 2.89% 5.77% 6.27%
Tax Burden Percent
73.82% 91.45% 77.04% 91.23% 51.57% 89.51% 69.38% 72.62% 68.59% 106.60% 79.08%
Interest Burden Percent
87.51% 84.82% 74.60% 106.34% 49.23% 124.54% 76.56% 80.31% 68.95% 77.21% 82.00%
Effective Tax Rate
26.18% 8.55% 22.96% 0.00% 48.43% 0.00% 30.62% 27.38% 31.41% 13.74% 25.87%
Return on Invested Capital (ROIC)
10.12% 12.31% 10.18% -41.55% 3.73% -22.85% 7.44% 9.16% 8.91% 12.88% 14.82%
ROIC Less NNEP Spread (ROIC-NNEP)
8.54% 10.81% 5.91% -60.02% -114.83% -32.06% 6.31% 8.07% -7.43% 8.40% 10.17%
Return on Net Nonoperating Assets (RNNOA)
1.94% 4.85% 1.08% -16.80% -0.46% -18.49% 4.00% 5.77% -0.33% 0.30% 1.13%
Return on Equity (ROE)
12.06% 17.17% 11.26% -58.35% 3.28% -41.34% 11.43% 14.93% 8.59% 13.18% 15.95%
Cash Return on Invested Capital (CROIC)
-37.85% 19.02% 79.05% 73.84% 10.60% 10.23% 9.36% 9.73% 12.44% -96.66% -101.87%
Operating Return on Assets (OROA)
6.65% 7.20% 6.03% -29.12% 2.86% -19.61% 6.87% 8.27% 5.20% 5.46% 7.60%
Return on Assets (ROA)
4.30% 5.59% 3.47% -28.26% 0.73% -21.87% 3.65% 4.82% 2.46% 4.49% 4.93%
Return on Common Equity (ROCE)
12.06% 17.17% 11.26% -58.35% 3.28% -41.34% 11.43% 14.93% 8.59% 13.18% 15.95%
Return on Equity Simple (ROE_SIMPLE)
-10.44% 0.00% -34.65% -35.65% -8.24% 0.00% 9.66% 10.92% 11.18% 0.00% 9.80%
Net Operating Profit after Tax (NOPAT)
24 36 26 -110 8.20 -78 28 35 21 31 35
NOPAT Margin
5.17% 7.15% 5.10% -21.89% 1.66% -15.72% 5.52% 7.04% 4.20% 6.05% 7.17%
Net Nonoperating Expense Percent (NNEP)
1.58% 1.50% 4.26% 18.47% 118.56% 9.21% 1.13% 1.09% 16.34% 4.48% 4.65%
Return On Investment Capital (ROIC_SIMPLE)
1.69% 2.60% - - - -5.26% - - - 2.01% -
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
86.32% 82.12% 82.76% 82.17% 86.72% 83.93% 84.05% 82.31% 85.80% 81.27% 81.80%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
93.00% 92.18% 93.38% 131.28% 96.79% 122.46% 92.05% 90.31% 93.88% 92.99% 90.33%
Earnings before Interest and Taxes (EBIT)
32 39 34 -158 16 -111 40 48 30 36 47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
38 46 40 -149 26 -102 50 58 39 46 57
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.58 1.47 1.36 0.90 0.98 0.92 1.10 1.26 1.36 1.38 1.62
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.63 0.56 0.50 0.32 0.42 0.39 0.53 0.60 0.63 0.63 0.71
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 11.38 11.55 12.10 18.61 16.54
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8.79% 8.66% 8.27% 5.37% 6.05%
Enterprise Value to Invested Capital (EV/IC)
1.38 1.35 1.49 0.88 0.98 0.95 1.07 1.16 1.35 1.24 1.35
Enterprise Value to Revenue (EV/Rev)
0.83 0.69 0.40 0.26 0.41 0.62 0.78 0.89 0.64 0.90 1.04
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 25.95 50.02 8.20 8.85 6.29 8.49 8.45
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 10.20 10.91 7.73 10.32 9.96
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 241.38 13.73 14.46 10.31 13.43 13.53
Enterprise Value to Operating Cash Flow (EV/OCF)
7.64 6.76 5.56 3.97 7.29 9.01 9.47 10.39 7.73 10.68 18.12
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 6.28 1.00 0.67 8.77 8.82 11.30 11.85 10.89 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.78 0.81 0.03 0.03 0.11 0.75 0.66 0.72 0.14 0.73 0.87
Long-Term Debt to Equity
0.75 0.78 0.00 0.00 0.09 0.73 0.64 0.71 0.13 0.71 0.85
Financial Leverage
0.23 0.45 0.18 0.28 0.00 0.58 0.63 0.71 0.04 0.04 0.11
Leverage Ratio
2.53 2.71 2.59 2.61 2.54 2.62 2.55 2.62 2.61 2.84 2.92
Compound Leverage Factor
2.21 2.30 1.93 2.77 1.25 3.27 1.95 2.10 1.80 2.19 2.40
Debt to Total Capital
43.70% 44.67% 2.56% 2.45% 10.12% 42.72% 39.67% 41.96% 12.41% 42.21% 46.49%
Short-Term Debt to Total Capital
1.58% 1.49% 2.56% 2.45% 1.72% 1.01% 0.93% 0.92% 1.44% 0.97% 0.93%
Long-Term Debt to Total Capital
42.12% 43.19% 0.00% 0.00% 8.40% 41.72% 38.74% 41.04% 10.98% 41.25% 45.56%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
56.30% 55.33% 97.44% 97.55% 89.88% 57.28% 60.33% 58.04% 87.59% 57.79% 53.51%
Debt to EBITDA
-25.24 -17.38 -0.10 -0.10 3.04 25.61 3.31 3.41 0.64 3.10 3.09
Net Debt to EBITDA
-16.21 -7.57 1.09 0.66 -0.60 18.42 2.66 2.89 0.13 2.61 2.68
Long-Term Debt to EBITDA
-24.33 -16.80 0.00 0.00 2.52 25.01 3.23 3.34 0.57 3.03 3.03
Debt to NOPAT
-16.67 -12.84 -0.13 -0.12 -20.17 123.58 5.54 5.58 1.05 4.91 4.95
Net Debt to NOPAT
-10.70 -5.60 1.31 0.77 3.99 88.90 4.45 4.72 0.21 4.13 4.29
Long-Term Debt to NOPAT
-16.07 -12.41 0.00 0.00 -16.74 120.67 5.41 5.45 0.93 4.79 4.85
Altman Z-Score
1.64 1.44 1.37 0.90 1.34 1.03 1.41 1.47 1.44 1.35 1.44
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.81 1.47 1.42 1.38 1.72 1.24 1.20 1.24 1.44 1.00 1.20
Quick Ratio
1.70 1.40 1.36 1.31 1.61 1.16 1.15 1.17 1.34 0.94 1.12
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-322 306 975 818 107 57 53 62 14 -997 -1,080
Operating Cash Flow to CapEx
-3,540.17% 0.00% 1,460.06% 1,536.21% -2,349.46% 829.04% 873.26% 1,095.24% -1,441.88% 1,003.62% 1,392.78%
Free Cash Flow to Firm to Interest Expense
-35.15 31.56 96.25 79.34 10.09 5.67 5.07 5.53 1.35 -100.15 -113.51
Operating Cash Flow to Interest Expense
-12.83 13.70 9.07 10.38 -11.81 6.87 7.71 7.93 -9.71 9.92 8.76
Operating Cash Flow Less CapEx to Interest Expense
-13.19 13.80 8.45 9.70 -12.32 6.04 6.82 7.21 -10.39 8.93 8.13
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.95 0.92 0.91 0.93 0.89 0.87 0.86 0.85 0.85 0.78 0.79
Accounts Receivable Turnover
7.51 7.56 7.11 7.35 7.11 7.01 7.04 6.90 6.64 6.59 7.03
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
35.11 35.06 34.29 33.04 27.14 26.79 27.41 27.43 27.25 27.50 27.14
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
48.60 48.26 51.31 49.67 51.36 52.07 51.86 52.87 54.95 55.39 51.89
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
48.60 48.26 51.31 49.67 51.36 52.07 51.86 52.87 54.95 55.39 51.89
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
1,183 1,034 531 591 837 1,305 1,480 1,519 936 1,440 1,505
Invested Capital Turnover
1.96 1.72 2.00 1.90 2.25 1.45 1.35 1.30 2.12 2.13 2.07
Increase / (Decrease) in Invested Capital
345 -271 -949 -928 -99 -135 -25 -27 6.53 1,028 1,115
Enterprise Value (EV)
1,637 1,396 794 520 824 1,237 1,579 1,767 1,264 1,783 2,039
Market Capitalization
1,244 1,127 995 635 843 781 1,067 1,190 1,238 1,234 1,393
Book Value per Share
$9.19 $8.91 $8.53 $8.40 $10.33 $10.11 $11.53 $11.25 $10.96 $10.73 $10.18
Tangible Book Value per Share
($5.40) ($5.70) ($6.05) ($6.45) ($6.71) ($6.62) ($6.90) ($7.24) ($7.71) ($7.93) ($8.21)
Total Capital
1,402 1,383 752 724 953 1,482 1,605 1,624 1,039 1,543 1,605
Total Debt
613 618 19 18 96 633 637 681 129 651 746
Total Long-Term Debt
590 597 0.00 0.00 80 618 622 666 114 636 731
Net Debt
393 269 -201 -115 -19 456 512 577 26 548 646
Capital Expenditures (CapEx)
3.32 -1.04 6.29 6.96 5.33 8.35 9.15 8.13 7.00 9.83 5.98
Debt-free, Cash-free Net Working Capital (DFCFNWC)
24 -122 -46 3.59 80 -68 -40 -12 36 -87 -13
Debt-free Net Working Capital (DFNWC)
243 226 174 137 196 109 85 92 139 16 87
Net Working Capital (NWC)
221 205 155 119 179 95 70 77 124 1.01 72
Net Nonoperating Expense (NNE)
2.96 5.45 6.62 43 4.16 46 6.55 6.94 6.40 1.43 4.40
Net Nonoperating Obligations (NNO)
393 269 -201 -115 -19 456 512 577 26 548 646
Total Depreciation and Amortization (D&A)
5.56 7.12 6.52 9.03 11 9.29 9.49 9.29 9.35 9.56 9.45
Debt-free, Cash-free Net Working Capital to Revenue
1.19% -6.08% -2.29% 0.18% 4.01% -3.43% -1.97% -0.60% 1.84% -4.42% -0.67%
Debt-free Net Working Capital to Revenue
12.28% 11.23% 8.69% 6.83% 9.79% 5.49% 4.23% 4.63% 7.03% 0.81% 4.44%
Net Working Capital to Revenue
11.16% 10.21% 7.73% 5.95% 8.97% 4.74% 3.48% 3.88% 6.28% 0.05% 3.68%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.25 $0.37 $0.23 ($1.84) $0.05 ($1.50) $0.26 $0.34 $0.17 $0.35 $0.37
Adjusted Weighted Average Basic Shares Outstanding
84.44M 83.33M 83.89M 83.33M 82.86M 82.20M 82.54M 82.40M 81.89M 83.47M 82.13M
Adjusted Diluted Earnings per Share
$0.24 $0.37 $0.23 ($1.84) $0.05 ($1.50) $0.26 $0.34 $0.17 $0.35 $0.37
Adjusted Weighted Average Diluted Shares Outstanding
85.43M 83.33M 84.52M 83.33M 83.28M 82.20M 82.95M 82.66M 82.32M 84.12M 82.78M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
85.91M 85.83M 85.88M 85.87M 84.15M 84.12M 84.02M 83.94M 83.76M 83.03M 83.07M
Normalized Net Operating Profit after Tax (NOPAT)
29 58 40 27 13 -76 28 35 21 48 36
Normalized NOPAT Margin
6.23% 11.46% 7.90% 5.26% 2.54% -15.41% 5.52% 7.04% 4.20% 9.34% 7.32%
Pre Tax Income Margin
6.13% 6.63% 4.94% -33.26% 1.58% -27.97% 6.09% 7.78% 4.22% 5.41% 7.93%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
3.51 4.05 3.34 -15.30 1.50 -11.06 3.88 4.32 2.89 3.62 4.98
NOPAT to Interest Expense
2.59 3.70 2.57 -10.71 0.77 -7.74 2.69 3.14 1.98 3.12 3.69
EBIT Less CapEx to Interest Expense
3.14 4.15 2.72 -15.98 1.00 -11.89 3.00 3.59 2.22 2.63 4.35
NOPAT Less CapEx to Interest Expense
2.23 3.81 1.95 -11.39 0.27 -8.57 1.81 2.41 1.31 2.14 3.06
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-2.90% -1.72% -0.42% -0.41% -1.46% -1.52% 2.55% 23.07% 86.62% 133.44% 103.40%

Frequently Asked Questions About Pediatrix Medical Group's Financials

When does Pediatrix Medical Group's fiscal year end?

According to the most recent income statement we have on file, Pediatrix Medical Group's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Pediatrix Medical Group's net income changed over the last 10 years?

Pediatrix Medical Group's net income appears to be on an upward trend, with a most recent value of -$99.07 million in 2024, falling from $317.20 million in 2014. The previous period was -$60.41 million in 2023. See Pediatrix Medical Group's forecast for analyst expectations on what’s next for the company.

What is Pediatrix Medical Group's operating income?
Pediatrix Medical Group's total operating income in 2024 was -$68.71 million, based on the following breakdown:
  • Total Gross Profit: $2.01 billion
  • Total Operating Expenses: $2.08 billion
How has Pediatrix Medical Group revenue changed over the last 10 years?

Over the last 10 years, Pediatrix Medical Group's total revenue changed from $2.44 billion in 2014 to $2.01 billion in 2024, a change of -17.5%.

How much debt does Pediatrix Medical Group have?

Pediatrix Medical Group's total liabilities were at $1.39 billion at the end of 2024, a 1.2% increase from 2023, and a 3.4% increase since 2014.

How much cash does Pediatrix Medical Group have?

In the past 10 years, Pediatrix Medical Group's cash and equivalents has ranged from $9.82 million in 2022 to $1.12 billion in 2020, and is currently $229.94 million as of their latest financial filing in 2024.

How has Pediatrix Medical Group's book value per share changed over the last 10 years?

Over the last 10 years, Pediatrix Medical Group's book value per share changed from 22.55 in 2014 to 8.91 in 2024, a change of -60.5%.



This page (NYSE:MD) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners